Digital Nova Scotia and Life Sciences Nova Scotia sign MOU to accelerate digital health and life sciences innovation
Seven Life Sciences Nova Scotia member companies are heading to San Diego this June, joining the Atlantic Canada delegation at the BIO International Convention 2026 (June 22–25). Together, they represent the breadth and ambition of Nova Scotia’s life sciences sector: from biomaterials and cancer immunotherapy to wearable health technology and novel diagnostics.
BIO International is the world’s largest biotechnology conference and a cornerstone event for global life sciences business development. Each year, it brings together more than 20,000 leaders from biotechnology, biopharma, medtech, diagnostics, investment, and government from over 70 countries. For companies at all stages, BIO is a highly concentrated opportunity to build relationships, advance deals, and explore new markets in a single, global forum.
A key driver of BIO’s value is BIO Partnering™, the industry’s most established one-to-one partnering system. Through the platform, companies can identify potential partners, investors, customers, and collaborators and schedule targeted meetings weeks in advance.
Thousands of pre-arranged meetings take place onsite, and for Nova Scotia companies, this provides direct access to global pharmaceutical companies, strategic partners, venture capital firms, and decision-makers.
We have been working closely with participating member companies to support their readiness for the conference including: their strategic positioning, meeting preparation, and effective use of the BIO Partnering™ platform. Our goal is to ensure their participation translates into meaningful connections, increased international visibility, and growth for Nova Scotia’s life sciences sector.
Learn about our member companies attending BIO 2026:
3DBioFibR Inc.
Halifax-based biomaterials manufacturer producing collagen, chitosan, and spider silk fibers at commercial scale. Its patented dry spinning technology delivers biomimetic fibers for regenerative medicine and resorbable medical devices.
Myomar Molecular
Halifax-developed medical technology company commercializing the world’s first urine-based muscle health test. Launched in 2024 following Health Canada approval, the test supports early detection, clinical decision-making, and recovery tracking.
Oncolinc Therapeutics
Halifax-based preclinical biotechnology company developing first-in-class cancer immunotherapies targeting tumor-specific long non-coding RNAs.
Partner International Inc.
Global outsourced business development firm specializing in partnering, licensing, and mergers and acquisitions across pharma, biotech, and medtech, with more than $3 billion in completed transactions.
Sona Nanotech
Halifax-based nanotechnology company developing Targeted Hyperthermia Therapy for solid tumors using a patented gold nanorod platform, alongside advanced in vitro diagnostic applications.
Treventis Corporation
Biotechnology company focused on protein misfolding diseases including Alzheimer’s and ALS, using its patented Common Conformational Morphology platform to design small-molecule therapeutics validated through major global partnerships.
XO Technology Inc.
Halifax health technology company developing the XO Companion Ring, a wearable platform that monitors functional health in older adults through grip strength, gait, activity, and physiological signals.
Together, these companies reflect the strength, talent, and innovation of Nova Scotia’s life sciences ecosystem. We’re looking forward to supporting their success at BIO 2026, and to continue building Nova Scotia’s reputation as a competitive and collaborative life sciences jurisdiction.